Outcomes of minimal access retroperitoneal para-aortic lymphadenectomy in patients with locally advanced cervical cancer.


Journal

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
ISSN: 1364-6893
Titre abrégé: J Obstet Gynaecol
Pays: England
ID NLM: 8309140

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 6 5 2024
pubmed: 6 5 2024
entrez: 6 5 2024
Statut: ppublish

Résumé

To evaluate outcomes of laparoscopic retroperitoneal para-aortic lymphadenectomy for stage 1b3-3b cervical cancer. Pathology databases searched for all para-aortic lymphadenectomy cases 2005-2016. Descriptive statistics were used to analyse baseline characteristics, cox models for treatment affect after accounting for variables, and Kaplan Meier curves for survival (STATA v15). 191 patients had 1b3-3b cervical cancer of which 110 patients had Para-aortic lymphadenectomy. 8 (7.3%) patients stage 1b3, 82 (74.6%) stage 2b, and 20 (18.1%) stage 3b cervical cancer. Mean lymph node count 11.7 (SD7.6). The intra-operative and post-operative 30 day complication rates were 8.8% (CI: 4.3%, 15.7%) and 5.3% (CI: 1.9%, 11.2%) respectively.Para-aortic nodes were apparently positive on CT/MRI in 5/110 (5%) cases. Cancer was found in 10 (8.9%, CI: 4.3%, 15.7%) cases on histology, all received extended field radiotherapy. Only 2 were identified on pre-operative CT/MRI imaging. 3 of 10 suspected node-positive cases on CT/MRI had negative histology. Para-aortic lymphadenectomy led to alteration in staging and radiotherapy management in 8 (8%, CI: 3.7%, 14.6%) patients. Mean overall survival 42.81 months (SD = 31.79 months). Survival was significantly higher for women undergoing PAN (50.57 (SD 30.7) months) compared to those who didn't (31.27 (SD 32.5) months). Laparoscopic retroperitoneal para-aortic lymphadenectomy is an acceptable procedure which can guide treatment in women with locally advanced cervical cancer. We evaluated outcomes for patients with stage 1b3-3b cervical cancer that had lymph nodes removed prior to planning their chemoradiotherapy. There were 3 groups – patients that had their lymph nodes removed, those that did not and those that had their procedure abandoned so didn’t have their lymph nodes removed. We looked at the lymph nodes down the microscope to see if they contained cancer and compared this to their pre-operative imaging. 8 patients had a change to their staging and treatment because they were found to have cancer in the lymph nodes. We found that the keyhole procedure to remove lymph nodes is an acceptable procedure which can guide treatment in women with locally advanced cervical cancer.

Sections du résumé

BACKGROUND UNASSIGNED
To evaluate outcomes of laparoscopic retroperitoneal para-aortic lymphadenectomy for stage 1b3-3b cervical cancer.
METHODS UNASSIGNED
Pathology databases searched for all para-aortic lymphadenectomy cases 2005-2016. Descriptive statistics were used to analyse baseline characteristics, cox models for treatment affect after accounting for variables, and Kaplan Meier curves for survival (STATA v15).
RESULTS UNASSIGNED
191 patients had 1b3-3b cervical cancer of which 110 patients had Para-aortic lymphadenectomy. 8 (7.3%) patients stage 1b3, 82 (74.6%) stage 2b, and 20 (18.1%) stage 3b cervical cancer. Mean lymph node count 11.7 (SD7.6). The intra-operative and post-operative 30 day complication rates were 8.8% (CI: 4.3%, 15.7%) and 5.3% (CI: 1.9%, 11.2%) respectively.Para-aortic nodes were apparently positive on CT/MRI in 5/110 (5%) cases. Cancer was found in 10 (8.9%, CI: 4.3%, 15.7%) cases on histology, all received extended field radiotherapy. Only 2 were identified on pre-operative CT/MRI imaging. 3 of 10 suspected node-positive cases on CT/MRI had negative histology. Para-aortic lymphadenectomy led to alteration in staging and radiotherapy management in 8 (8%, CI: 3.7%, 14.6%) patients. Mean overall survival 42.81 months (SD = 31.79 months). Survival was significantly higher for women undergoing PAN (50.57 (SD 30.7) months) compared to those who didn't (31.27 (SD 32.5) months).
CONCLUSION UNASSIGNED
Laparoscopic retroperitoneal para-aortic lymphadenectomy is an acceptable procedure which can guide treatment in women with locally advanced cervical cancer.
We evaluated outcomes for patients with stage 1b3-3b cervical cancer that had lymph nodes removed prior to planning their chemoradiotherapy. There were 3 groups – patients that had their lymph nodes removed, those that did not and those that had their procedure abandoned so didn’t have their lymph nodes removed. We looked at the lymph nodes down the microscope to see if they contained cancer and compared this to their pre-operative imaging. 8 patients had a change to their staging and treatment because they were found to have cancer in the lymph nodes. We found that the keyhole procedure to remove lymph nodes is an acceptable procedure which can guide treatment in women with locally advanced cervical cancer.

Autres résumés

Type: plain-language-summary (eng)
We evaluated outcomes for patients with stage 1b3-3b cervical cancer that had lymph nodes removed prior to planning their chemoradiotherapy. There were 3 groups – patients that had their lymph nodes removed, those that did not and those that had their procedure abandoned so didn’t have their lymph nodes removed. We looked at the lymph nodes down the microscope to see if they contained cancer and compared this to their pre-operative imaging. 8 patients had a change to their staging and treatment because they were found to have cancer in the lymph nodes. We found that the keyhole procedure to remove lymph nodes is an acceptable procedure which can guide treatment in women with locally advanced cervical cancer.

Identifiants

pubmed: 38708782
doi: 10.1080/01443615.2024.2344529
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2344529

Auteurs

Claire Newton (C)

Gynaecology Oncology, University Hospitals Bristol NHS Foundation trust, Bristol, UK.
University of Bristol, Bristol, UK.
University College London Hospital NHS Foundation Trust, London, UK.

Radha Graham (R)

University College London Hospital NHS Foundation Trust, London, UK.

Viola Liberale (V)

University College London Hospital NHS Foundation Trust, London, UK.

Matthew Burnell (M)

MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.

Usha Menon (U)

MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.

Tim Mould (T)

University College London Hospital NHS Foundation Trust, London, UK.

Adeola Olaitan (A)

University College London Hospital NHS Foundation Trust, London, UK.

Nicola Macdonald (N)

University College London Hospital NHS Foundation Trust, London, UK.

Martin Widschwendter (M)

University College London Hospital NHS Foundation Trust, London, UK.
European Translational Oncology Prevention and Screening Institute, Leopold-Franzens-University of Innsbruck, Austria.

Kostas Doufekas (K)

University College London Hospital NHS Foundation Trust, London, UK.

Mary McCormack (M)

University College London Hospital NHS Foundation Trust, London, UK.

Anita Mitra (A)

University College London Hospital NHS Foundation Trust, London, UK.

Rupali Arora (R)

University College London Hospital NHS Foundation Trust, London, UK.

Ranjit Manchanda (R)

MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
The Royal London hospital, Barts Health NHS trust, London, UK.
Distinguished Infosys Chair in Oncology, All India institute of medical sciences (AIIMS), New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH